Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis
NCT06865417Phase 3Recruiting
- Sponsor
- Alfasigma
- Start
- Sep 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of filgotinib in ulcerative colitis (UC), sponsored by Alfasigma. Started Sep 2025; status: recruiting.
02
Drugs
filgotinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06865417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06865417.